AVIR Atea Pharmaceuticals, Inc.

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

$5.76  +0.07 (1.23%)
As of 10/03/2022 15:59:53 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/30/2020
Outstanding shares:  83,258,603
Average volume:  673,255
Market cap:   $466,248,177
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BLN9Z50
Valuation   (See tab for details)
PE ratio:   5.24
PB ratio:   0.70
PS ratio:   1.63
Return on equity:   7.12%
Net income %:   16.96%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy